This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Diabetes Mellitus, Type 2 or Hydroxymethylglutaryl-CoA Reductase Inhibitors
and you are
between 18 and 70
years old
The phase for this study is not defined.
Show me locations

The purpose

The primary objective of the present study is to evaluate the effect of HMG-CoA reductase inhibition during 14 days on the postprandial plasma GLP-1 response in healthy individuals. Secondary objectives include the evaluation of HMG-CoA reductase inhibition on postprandial glucose tolerance, gallbladder emptying, gastric emptying, plasma responses of lipids, bile acids and pancreatic and enteric hormones known to influence glucose metabolism and appetite, and faecal content of bile acids and gut microbiota composition.

Provided treatments

  • Drug: Atorvastatin
  • Other: Placebo

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03018444. The sponsor of the trial is University Hospital, Gentofte, Copenhagen and it is looking for 15 volunteers for the current phase.
Official trial title:
The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion